Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.
about
Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytesClinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitorHistone deacetylases as targets for treatment of multiple diseasesNew and emerging HDAC inhibitors for cancer treatmentNew strategies in lung cancer: epigenetic therapy for non-small cell lung cancerThe role of epigenetics in resistance to Cisplatin chemotherapy in lung cancerCLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells.Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.Class II histone deacetylases: from sequence to function, regulation, and clinical implication.Histone deacetylase 10 relieves repression on the melanogenic program by maintaining the deacetylation status of repressors.Lung cancer: a modified epigenome.Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer TherapyGenomic alterations of primary tumor and blood in invasive ductal carcinoma of breastNew histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Histone deacetylase: a potential therapeutic target for fibrotic disordersHistone deacetylases and cancer.Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.Histone deacetylase inhibitors: discovery and development as anticancer agents.HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.Nonhistone protein acetylation as cancer therapy targets.Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential.HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities.Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway.Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.Epigenetic mechanisms in commonly occurring cancers.Epigenetics of lung cancer.Development of histone deacetylase inhibitors for cancer treatment.Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip).Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigeneticsAddition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagyHistone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expressionHistone deacetylase regulation of ATM-mediated DNA damage signaling.Targeting histone deacetylases for the treatment of diseaseEstrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cellsHDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
P2860
Q24676765-3E44EAC4-F8E5-4832-BD8B-6DA94D10A38BQ26747768-C8AC75FE-6DCF-4293-82B3-E921E5E700C8Q27000389-2F1CB519-DB3F-45A9-8845-AC99B6F04478Q27022413-32FFF412-E2A5-41B3-964D-8F0A49229A34Q28236190-29C42A4C-0562-4AEE-B0EC-921057FC9F91Q28387891-C200BFD0-80B2-4699-A9BD-29DAEE54C321Q33268742-AD7E5557-E94F-400F-B130-8D7A19423EB2Q33361466-13254EC7-9344-4CC3-9ED0-92F479E1D02BQ33724483-873588A2-05AF-45F9-B035-5048F22E30FBQ33748031-EF790605-1942-4A87-BD1F-950CCE6A2329Q33781123-91ABF920-BAAA-4501-BB41-C59993096D7CQ33802356-96990B79-C571-4686-9585-9812453A1864Q33833204-310D14FE-3EED-43BA-AEEF-1E56DA938A68Q34101029-E2B4108E-97B8-41F8-B0BF-00CB6C0F0A91Q34224278-24424D84-178A-494A-9E37-11576A9951C8Q34257607-AB094084-974F-4E62-A517-3F6BAFE7E780Q34298745-11AA2D77-551E-4B56-B6D5-D5DFFC1D348CQ34371426-07F987F8-C2E2-41DB-82FE-7F7D513909F1Q34470150-C9136ADA-B75E-4593-BA9F-C5CD5157653DQ35203538-E49D46C2-2B8C-4B95-9888-0A73DBD79D3BQ35643696-4FDC07D1-8A69-4580-B369-BBF626D0D385Q35739676-D719BF74-5A83-489B-AE82-66167E6B15F9Q35806891-F173F81D-C5A4-47A6-A1CE-1D05EBE9533DQ35824343-E7C62BF4-64E8-4EC0-ADF1-0BBAE1D583EDQ35975127-D2B92836-C9DD-4D4F-B6C5-5A0F4EFEF291Q36028506-43220EDC-C5C4-40E2-8053-D51856097A91Q36070032-051B91D3-E6DC-4A55-BC9F-D6E7B6B9B651Q36214527-78EC1E0D-2133-43A7-85E6-B041B53CDB23Q36286662-6255D260-CBB6-4620-9380-6E58DB3FA4A7Q36505767-41564CED-A4F2-4F7E-9642-9CA672AB0CD0Q36788512-9F4668CF-5AF7-41FD-8E8E-9EBA00F1AF71Q36846714-91F9DE26-D336-4AC0-AF89-D82BCCB78E80Q37062105-0FF2EC43-F1CD-40A8-AD7F-C0EF4A0BEDF9Q37141408-6F32F9FA-B874-4A79-94A9-B89FDAB97245Q37201244-89B3D27D-4BCF-4F8B-B013-4A37FCAAF816Q37291739-B0BD852B-EDD4-402E-8238-A83D33E371B6Q37296159-6D7FAD03-750D-4023-95DD-44594B477895Q37327681-80DC6E0F-4402-4B67-AACF-CBBDAB97E262Q37372149-D4155F27-A280-44EA-B346-0961F97D1C4DQ37399295-1D6F32EC-A51C-43D5-885B-F748F4F6FFCB
P2860
Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Reduced expression of class II ...... nosis in lung cancer patients.
@ast
Reduced expression of class II ...... nosis in lung cancer patients.
@en
Reduced expression of class II ...... nosis in lung cancer patients.
@nl
type
label
Reduced expression of class II ...... nosis in lung cancer patients.
@ast
Reduced expression of class II ...... nosis in lung cancer patients.
@en
Reduced expression of class II ...... nosis in lung cancer patients.
@nl
prefLabel
Reduced expression of class II ...... nosis in lung cancer patients.
@ast
Reduced expression of class II ...... nosis in lung cancer patients.
@en
Reduced expression of class II ...... nosis in lung cancer patients.
@nl
P2093
P50
P356
P1476
Reduced expression of class II ...... gnosis in lung cancer patients
@en
P2093
Hiroko Saito
Hirotaka Osada
Yoshio Tatematsu
P356
10.1002/IJC.20395
P577
2004-10-01T00:00:00Z